

Roberta Modica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4200200/publications.pdf>

Version: 2024-02-01

54
papers

895
citations

516681

16
h-index

580810

25
g-index

57
all docs

57
docs citations

57
times ranked

1038
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic arterial embolization in patients with neuroendocrine tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 43.	8.6	50
2	A rare rarity: Neuroendocrine tumor of the esophagus. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 92-107.	4.4	39
3	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 78-84.	3.6	39
4	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 9-20.	3.3	38
5	Nutrition and neuroendocrine tumors: An update of the literature. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 159-167.	5.7	38
6	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	3.6	32
7	The safety of available treatments options for neuroendocrine tumors. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1149-1161.	2.4	29
8	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. <i>Cancers</i> , 2019, 11, 1332.	3.7	28
9	No Phenotypic Differences for Polycystic Ovary Syndrome (PCOS) Between Women With and Without Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 203-211.	3.6	27
10	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020, 25, 259-265.	3.7	27
11	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 649496.	3.5	27
12	Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. <i>Frontiers in Endocrinology</i> , 2020, 11, 604341.	3.5	27
13	Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric caseâ€control study. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 849-857.	3.3	27
14	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , 2020, 69, 441-450.	2.3	26
15	GLP-1: benefits beyond pancreas. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 1143-1153.	3.3	25
16	Therapeutic sequences in patients with grade 1â2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , 2019, 66, 417-424.	2.3	25
17	Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e316-e327.	3.6	21
18	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2022, 5, e220290.	5.9	21

#	ARTICLE	IF	CITATIONS
19	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , 2021, 44, 989-994.	3.3	18
20	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. <i>Nutrients</i> , 2020, 12, 1021.	4.1	17
21	The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. <i>Endocrine</i> , 2018, 62, 46-56.	2.3	16
22	Efficacy and Safety of Everolimus in Extrapaneatic Neuroendocrine Tumor: A Comprehensive Review of Literature. <i>Oncologist</i> , 2016, 21, 875-886.	3.7	15
23	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1209-1224.	2.5	14
24	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 563-579.	5.7	14
25	Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	14
26	Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1373-1380.	3.3	13
27	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	2.5	13
28	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 511-525.	5.7	13
29	Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2227-2234.	3.3	13
30	Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. <i>Frontiers in Endocrinology</i> , 2021, 12, 651438.	3.5	13
31	Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?. <i>Journal of Translational Medicine</i> , 2021, 19, 324.	4.4	13
32	Open issues on G3 neuroendocrine neoplasms: back to the future. <i>Endocrine-Related Cancer</i> , 2018, 25, R375-R384.	3.1	12
33	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021, 53, 367-374.	0.9	12
34	Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature. <i>Frontiers in Endocrinology</i> , 2020, 11, 397.	3.5	11
35	Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. <i>Frontiers in Oncology</i> , 2020, 10, 1047.	2.8	11
36	Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 389-403.	2.4	11

#	ARTICLE	IF	CITATIONS
37	Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. <i>Endocrine</i> , 2015, 49, 854-858.	2.3	10
38	Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1224.	2.4	10
39	Autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) in Sicily: confirmation that R203X is the peculiar AIRE gene mutation. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 384-8.	3.3	10
40	Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. <i>Frontiers in Endocrinology</i> , 2021, 12, 665698.	3.5	9
41	Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. <i>Journal of Clinical Medicine</i> , 2020, 9, 588.	2.4	8
42	Prognostic significance of laterality in lung neuroendocrine tumors. <i>Endocrine</i> , 2022, 76, 733-746.	2.3	8
43	Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. <i>Endocrine</i> , 2015, 49, 274-278.	2.3	7
44	Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. <i>Endocrine</i> , 2022, 75, 623-634.	2.3	6
45	Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 713.	2.4	6
46	Pituitary function and morphology in Fabry disease. <i>Endocrine</i> , 2015, 50, 483-488.	2.3	5
47	Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences. <i>Neuroendocrinology</i> , 2020, 111, 696-704.	2.5	5
48	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , 2021, 13, 5831.	3.7	5
49	Diagnosis of Flierâ€™s syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature. <i>Endocrine</i> , 2020, 69, 73-78.	2.3	4
50	Characterization of Atypical Pheochromocytomas with Correlative MRI and Planar/Hybrid Radionuclide Imaging: A Preliminary Study. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9666.	2.5	4
51	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. <i>Annals of Surgical Oncology</i> , 2022, 29, 5568-5577.	1.5	4
52	Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 373-374.	3.3	3
53	An incidental rectal neuroendocrine microcarcinoma (â€™microâ€™NECâ€™) coexistent with a high grade adenoma. <i>Pathology International</i> , 2020, 70, 300-302.	1.3	1
54	Role of metformin on recurrence-free survival in neuroendocrine tumors. <i>Endocrine Abstracts</i> , 0, , .	0.0	1